Malignant Neoplasm of Breast Clinical Trial
Examining the analgesic effect of ultrasound guided Pectoral Blocks on analgesic opioid
consumption after surgical removal of breast tissue.
This study's uniqueness is in the quantification of the analgesic effect of regional
anesthesia on its influence to reduce the use of opioid substances, and the variety of side
effects associated with them, which has yet to been described in literature.
This is a prospective, observational,single center study which will be conducted at the Rabin
Medical Center (Beilinson Campus), Petach Tikva, Israel, a tertiary university hospital.
Sixty women undergoing breast tissue resection under general anesthesia will be enrolled
after filling out an informed consent form.
As standard protocol in our hospital all participants will include women undergoing the
surgery under general anesthesia, and the an addition of regional PEC block anesthesia.
The use of opioid substances during surgery will be done under the discretion of the
anesthesiologist, according to accepted professional criteria.
All participants will undergo the the PEC block before surgery under general anesthesia under
aseptic conditions, which is the standard analgesia protocol in our department.
Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following
the identification, the investigator will inject the anesthetic solution which will contain
the conventional 25 cc of Bupivacaine 0.25-0.5% .
The concentration is determined by the upper dose limit to 2 mg / kg 11.
At the end of the operation all participants will be transferred to the post anesthesia
recovery supervision unit, as standard protocol. The women will receive analgesic treatment
according to accepted recovery unit protocols of Beilinson Hospital, and according to the
professional discretion of the anesthesiologist in charge of the recovery unit.
On postoperative day one all participants will be asked to fill out a questionnaire that
measures the degree of their pain after surgery, and the extent of the expected side effects
from exposure to opioids This questionnaire is based on a questionnaire measuring quality QoR
recovery from general anesthesia.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02378337 -
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
|
N/A | |
| Completed |
NCT01953003 -
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT01395706 -
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes
|
Phase 2 | |
| Enrolling by invitation |
NCT05486520 -
Low-field MRI for Breast Cancer Screening
|
N/A | |
| Completed |
NCT05159778 -
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
|
Phase 2 | |
| Active, not recruiting |
NCT03379428 -
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02891681 -
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
|
N/A | |
| Withdrawn |
NCT03261323 -
Breast Reconstruction Following Breast Cancer in Very High Risk Patients
|
N/A | |
| Recruiting |
NCT04669873 -
Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery
|
N/A | |
| Completed |
NCT02408393 -
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
|
Phase 3 | |
| Completed |
NCT03289819 -
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
|
Phase 2 | |
| Completed |
NCT03159195 -
Ibrance Real World Insights
|
||
| Completed |
NCT03425656 -
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05033756 -
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
|
Phase 2 | |
| Not yet recruiting |
NCT01641003 -
Isolation and Characterization of Cancer Stem Cells Using iFP Technique
|
N/A | |
| Active, not recruiting |
NCT05364450 -
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03435952 -
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
|
Phase 1 | |
| Active, not recruiting |
NCT02204098 -
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT06251544 -
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02187991 -
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
|
Phase 2 |